kabutan

DAIICHI SANKYO COMPANY, LIMITED(4568) Summary

4568
TSE Prime
DAIICHI SANKYO COMPANY, LIMITED
3,361.0
JPY
+1.0
(+0.03%)
Dec 12, 3:30 pm JST
21.57
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
3,365
Dec 12, 11:48 pm JST
Summary Chart Historical News Financial Result
PER
21.6
PBR
3.76
Yield
2.32%
Margin Trading Ratio
13.74
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
3,350.0 JPY 21.54 USD
Previous Close Dec 11
3,360.0 JPY 21.52 USD
High Dec 12, 10:24 am
3,389.0 JPY 21.79 USD
Low Dec 12, 9:00 am
3,345.0 JPY 21.51 USD
Volume
6,751,400
Trading Value
0.02T JPY 0.15B USD
VWAP
3366.62 JPY 21.61 USD
Minimum Trading Value
336,100 JPY 2,157 USD
Market Cap
6.37T JPY 0.04T USD
Number of Trades
6,346
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
9,103
1-Year High Apr 25, 2025
29,113
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 100,100 3,675,500 36.72
Nov 28, 2025 152,600 2,863,900 18.77
Nov 21, 2025 124,500 2,941,400 23.63
Nov 14, 2025 103,000 3,504,300 34.02
Nov 7, 2025 88,100 3,555,500 40.36
Company Profile
DAIICHI SANKYO COMPANY, LIMITED is a major pharmaceutical company in Japan, with strengths in cardiovascular and infectious diseases. The company has partnered with AstraZeneca of the UK for new cancer drugs.
Sector
Pharmaceuticals
DAIICHI SANKYO COMPANY, LIMITED primarily engages in the research, development, manufacturing, and sales of pharmaceuticals, with a broad range of operations both domestically and internationally. In Japan, the company operates through multiple subsidiaries involved in pharmaceutical manufacturing, research and development and sales of over-the-counter drugs, and vaccine research, development, and production, showcasing a diverse group of companies with varied functions. The company has partnered with AstraZeneca in the oncology field. Internationally, DAIICHI SANKYO has subsidiaries in the United States, Europe, China, Brazil, and other regions, conducting pharmaceutical research, development, manufacturing, and sales in each area. In the United States, the company has established a holding company, while in Europe, it operates through numerous group companies across various countries. DAIICHI SANKYO leverages its global network for research, development, manufacturing, and sales to enhance its competitiveness in the world market.